To the best of our knowledge, this study represents one of the largest efforts to assess the associations between MIP-1α, VEGF, and TGF-α serum levels and multiple myeloma risk and progression using prospective longitudinal samples from the general population. This evidence concerns the gene CCL3 and plasma cell myeloma.